Rapid reversal of endothelial dysfunction in hypercholesterolaemic rabbits treated with simvastatin and pravastati n

Clinical and Experimental Pharmacology and Physiology

Volumn 24, Issue 12, 1997, Pages 948-953

  Ribeiro Jorge, Paulo A ^a,b   Osaki, Michiko R ^a   De Almeida, Eros ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b NONE   (Brazil)

Author keywords

Endothelium dysfunction; Endothelium dependent relaxation; Hypercholesterolaemia; Pravastatin; Rabbits; Simvastatin

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MALONALDEHYDE; PRAVASTATIN; SIMVASTATIN;

ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENDOTHELIUM; ENDOTHELIUM CELL; HISTOLOGY; HYPERCHOLESTEROLEMIA; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RABBIT; VASODILATATION;

EID: 0030784638     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1997.tb02724.x     Document Type: Article

References (37)

1. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trials results: I and II. JAMA 1970; 213: 1143-52.
2. Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 1990; 323: 1289-98.
3. Meredith IT, Yeung AC, Weidinger FF et al. Role of impaired endothelium-dependent vasodilation in ischemic manifestations of coronary artery disease. Circulation 1993; 87 (suppl. V): V56-66.
4. Moncada S, Radomski MW, Palmer RM. Endothelium-derived relaxing factor: Identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem. Pharmacol. 1988; 37: 2495-501.
5. Garg UC, Hassid A. Nitric oxide generating vasodilators and 8-bromocyclic GMP inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest. 1990; 83: 1774-7.
6. Bath PMW, Hassel DG, Gladwin AM, Palmer RMJ, Martin JF. Nitric oxide and prostacyclin: Divergence of inhibitory effects on monocyte chemotaxis and adhesion in vitro. Arterioscler. Thromb. 1991; 11: 254-60.
7. Ribeiro Jorge PA, Osaki R, Metze K. Effects of simvastatin and pravastatin on endothelium-dependent relaxation in hypercholesterolemic rabbits. Exp. Toxicol. Pathol. 1994; 46: 465-9.
8. Osborn AJ, Lento PH, Siegrifrid MR, Stahal GL, Fusman B, Lefer AM. Cardiovascular effects of acute hypercholesterolemia in rabbits. Reversal with lovastatin treatment. J. Clin. Invest. 1989; 83: 466-73.
9. Leung W-H, Lau C-P, Wong C-K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993; 341: 1496-500.
10. Egashira K, Hirooka Y, Kai H et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519-24.
11. Treasure CB, Klein L, Weintraub WS et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 1995; 332: 481-7.
12. Mügge A, Elwell JH, Peterson TE, Hofmayer TG, Heistad DD, Harrison DG. Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits. Circ. Res. 1991; 69: 1293-300.
13. Keaney JF, Gaziano JM, Xu-A et al. Low-dose alpha-tocopherol improves and high-dose alpha-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J. Clin. Invest. 1994; 93: 844-55.
14. Stewart-Lee, Forster LA, Zadeh-Nourroz GAA, Angaard EE. Vitamin E protects against impairment of endothelium-mediated relaxations in cholesterol-fed rabbits. Arterioscler. Thromb. 1994; 14: 494-9.
15. Naito HK, David JA. Laboratory considerations: Determination of cholesterol, triglycerides, phospholipids and others lipids in blood and tissues. Lab. Res. Methods Biol. Med. 1984; 10: 1-76.
16. Folch JML, Stanley GHS. A simple method for the isolation and purification of total lipids from animal tissue. J. Biol. Chem. 1965; 226: 1780-6.
17. Cassini AF, Ferrali M, Pompella A, Maellaro E, Comporti M. Lipid peroxidation and cellular damage in extrahepatic tissue of bromobenzene-intoxicated mice. Am. J. Pathol. 1986; 123: 520-31.
18. Snedecor GW, Cochran WG. Statistical methods, 7th edn. Iowa State University Press, Ames, 1989.
19. Flavahan NA. Atherosclerosis or lipoprotein-induced endothelial dysfunction. Circulation 1992; 85: 1927-38.
20. Subbaiah PV, Chen CH, Bagdade JD, Albers JJ. Role of low density lipoprotein in the activation of plasma lysolecithin acyltransferase activity. Effect of chemical and enzymatic modifications of the lipoprotein on enzyme activity. Atherosclerosis 1985; 54: 99-110.
21. Quiao Y, Yokoyama M, Kohji K, Asano G. Effect of vitamin E on vascular integrity in cholesterol-fed guinea pig. Arterioscler. Thromb. 1993; 13: 1885-92.
22. Simionescu N, Simionescu M. Endothelial cell biology in health and disease. Plenum Press, New York. 1988.
23. Tomita T, Ezaki M, Nakamura K, Ionue Y. Rapid and reversible inhibition by low density lipoprotein of the endothelium-dependent relaxation to hemostatic substances in porcine coronary arteries. Circ. Res. 1990; 66: 18-27.
24. Hoffman R, Brook GJ, Aviram MM. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies. Atherosclerosis 1992; 93: 105-13.
25. Giroux LM, Davigni J, Naruszewicz M. Sinvastatin inhibits the oxidation of low density lipoprotein by activated human monocytes-derived macrophages. Biochem. Biophys. Acta 1993; 1165: 335-8.
26. Franceschini G, Cassinotti M, Vecchio G et al. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler. Thromb. 1994; 14: 1569-75.
27. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 1995; 36: 211-28.
28. Rothblat GH, Mahlberg FH, Johnson WJ, Phillips MC. Apolipoproteins, membrane cholesterol domains and the regulation of cholesterol efflux. J. Lipid Res. 1992; 33: 1091-7.
29. Oram JF. Cholesterol trafficking in cells. Curr. Opin. Lipidol. 1990; 1: 416-21.
30. Schimitz GG, Assman H, Robenec H, Brennhausen B. Tangier disease: A disorder of intracellular membrane traffic. Proc. Natl Acad. Sci. USA 1985; 82: 6305-9.
31. Corsini A, Bernini F, Quarato P et al. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology 1966; 87: 458-68.
32. Solenen R, Nyssonen K, Porkkala-Sarataho E, Solenen JT. The Kuopio Atherosclerosis Prevention Study (KAPS): Effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am. J. Cardiol. 1995; 76: C34-9.
33. Ribeiro Jorge PA, Osaki RM, Almeida E, Credidio Neto L, Metze K. Effects of vitamin E on endothelium-dependent coronary flow in hypercholesterolemic dogs. Atherosclerosis 1996; 126: 43-51.
34. Mosley St, Kalinoswki SS, Schafer BL, Tanaka RD. Tissue selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens. J. Lipid Res. 1989; 30: 1411-20.
35. Pentikainen PJ, Saraheimo M, Schartz JI et al. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J. Clin. Pharmacol. 1992; 32: 136-40.
36. Germerhausen JI, Hunt VM, Bostedor RG, Bailey PJ, Karkas JD, Alberts AW. Tissue selectivity of the cholesterol-lowering agents lovastatin, sinvastatin and pravastatin in rats in vivo. Biochem. Biophys. Res. Commun. 1989; 158: 667-75.
37. Gerson RJ, Macdonald JS, Alberts AW et al. Animal safely and toxicology of sivastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors. Am. J. Med. 1988; 87: 4A-28S-38.